Sorin invests $5.4M in percutaneous mitral valve developer

Sorin Group has made a minority investment with option-to-buy in HighLife, an early-stage company focused on the development of a transcatheter mitral valve replacement system to treat patients with mitral regurgitation.

HighLife, located in Paris, was co-founded in 2010 by Georg Börtlein, who was a co-founder and chief operating officer at CoreValve, a developer of transcatheter aortic valve replacement products.

Sorin's EUR4.2 million ($5.44 million U.S.) initial investment will finance ongoing product development and clinical testing of the technology. Under the terms of the agreement, Milan, Italy-based Sorin also has acquired an exclusive option to acquire the company in the future. This investment is meant to complement the recently announced investment in Cardiosolutions, which is developing a percutaneous mitral repair system, according to Sorin.

 

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup